Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 1 of 1 for:    NCT02443077
Previous Study | Return to List | Next Study

Ibrutinib Before and After Stem Cell Transplant in Treating Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT02443077
Recruitment Status : Recruiting
First Posted : May 13, 2015
Last Update Posted : October 18, 2019
Sponsor:
Information provided by (Responsible Party):
National Cancer Institute (NCI)

Brief Summary:
This randomized phase III trial studies ibrutinib to see how well it works compared to placebo when given before and after stem cell transplant in treating patients with diffuse large B-cell lymphoma that has returned after a period of improvement (relapsed) or does not respond to treatment (refractory). Before transplant, stem cells are taken from patients and stored. Patients then receive high doses of chemotherapy to kill cancer cells and make room for healthy cells. After treatment, the stem cells are then returned to the patient to replace the blood-forming cells that were destroyed by the chemotherapy. Ibrutinib is a drug that may stop the growth of cancer cells by blocking a protein that is needed for cell growth. It is not yet known whether adding ibrutinib to chemotherapy before and after stem cell transplant may help the transplant work better in patients with relapsed or refractory diffuse large B-cell lymphoma.

Condition or disease Intervention/treatment Phase
Recurrent Diffuse Large B-Cell Lymphoma Activated B-Cell Type Refractory Diffuse Large B-Cell Lymphoma Activated B-Cell Type Procedure: Autologous Bone Marrow Transplantation Procedure: Autologous Hematopoietic Stem Cell Transplantation Drug: Carmustine Drug: Cyclophosphamide Drug: Cytarabine Drug: Etoposide Drug: Ibrutinib Other: Laboratory Biomarker Analysis Drug: Melphalan Other: Pharmacogenomic Study Other: Placebo Phase 3

  Show Detailed Description

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 302 participants
Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: Triple (Participant, Care Provider, Investigator)
Primary Purpose: Treatment
Official Title: A Randomized Double-Blind Phase III Study of Ibrutinib During and Following Autologous Stem Cell Transplantation Versus Placebo in Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma of the Activated B-Cell Subtype
Actual Study Start Date : July 6, 2016
Estimated Primary Completion Date : October 7, 2022

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Lymphoma
Drug Information available for: Ibrutinib

Arm Intervention/treatment
Experimental: Arm I (ibrutinib, chemotherapy, autoHCT)

CONDITIONING REGIMEN: Investigators may choose to use either the BEAMi or CBVi regimen.

BEAMi: Patients receive ibrutinib PO on days -6 to -1 or days -7 to -2 if a day of rest is planned, carmustine IV over 2 hours on day -6, etoposide IV BID over 1-2 hours and cytarabine IV BID over 1-2 hours on days -5 to -2, and melphalan IV over 20-30 minutes on day -1.

CBVi: Patients receive ibrutinib PO on days -6 to -1 or days -7 to -2 if a day of rest is planned, carmustine IV over 2 hours on day -6, etoposide IV over 4 hours on day -4, and cyclophosphamide IV on day -2.

TRANSPLANT: In both arms, patients undergo autologous hematopoietic progenitor cell or bone marrow transplant on day 0.

CONTINUATION REGIMEN: Beginning 30-60 days after transplant, patients receive ibrutinib PO on days 1-28. Treatment repeats every 28 days for 12 cycles in the absence of disease progression or unacceptable toxicity.

Procedure: Autologous Bone Marrow Transplantation
Undergo autologous hematopoietic progenitor cells or bone marrow transplant
Other Names:
  • ABMT
  • Autologous Blood and Marrow Transplantation
  • Autologous Bone Marrow Transplant
  • Autologous Marrow Transplantation

Procedure: Autologous Hematopoietic Stem Cell Transplantation
Undergo autologous hematopoietic progenitor cells or bone marrow transplant
Other Names:
  • Autologous Hematopoietic Cell Transplantation
  • autologous stem cell transplantation

Drug: Carmustine
Given IV
Other Names:
  • BCNU
  • Becenum
  • Becenun
  • BiCNU
  • Bis(chloroethyl) Nitrosourea
  • Bis-Chloronitrosourea
  • Carmubris
  • Carmustin
  • Carmustinum
  • FDA 0345
  • N,N''-Bis(2-chloroethyl)-N-nitrosourea
  • Nitrourean
  • Nitrumon
  • SK 27702
  • SRI 1720
  • WR-139021

Drug: Cyclophosphamide
Given IV
Other Names:
  • (-)-Cyclophosphamide
  • 2H-1,3,2-Oxazaphosphorine, 2-[bis(2-chloroethyl)amino]tetrahydro-, 2-oxide, monohydrate
  • Carloxan
  • Ciclofosfamida
  • Ciclofosfamide
  • Cicloxal
  • Clafen
  • Claphene
  • CP monohydrate
  • CTX
  • CYCLO-cell
  • Cycloblastin
  • Cycloblastine
  • Cyclophospham
  • Cyclophosphamid monohydrate
  • Cyclophosphamide Monohydrate
  • Cyclophosphamidum
  • Cyclophosphan
  • Cyclophosphane
  • Cyclophosphanum
  • Cyclostin
  • Cyclostine
  • Cytophosphan
  • Cytophosphane
  • Cytoxan
  • Fosfaseron
  • Genoxal
  • Genuxal
  • Ledoxina
  • Mitoxan
  • Neosar
  • Revimmune
  • Syklofosfamid
  • WR- 138719

Drug: Cytarabine
Given IV
Other Names:
  • .beta.-Cytosine arabinoside
  • 1-.beta.-D-Arabinofuranosyl-4-amino-2(1H)pyrimidinone
  • 1-.beta.-D-Arabinofuranosylcytosine
  • 1-Beta-D-arabinofuranosyl-4-amino-2(1H)pyrimidinone
  • 1-Beta-D-arabinofuranosylcytosine
  • 1.beta.-D-Arabinofuranosylcytosine
  • 2(1H)-Pyrimidinone, 4-Amino-1-beta-D-arabinofuranosyl-
  • 2(1H)-Pyrimidinone, 4-amino-1.beta.-D-arabinofuranosyl-
  • Alexan
  • Ara-C
  • ARA-cell
  • Arabine
  • Arabinofuranosylcytosine
  • Arabinosylcytosine
  • Aracytidine
  • Aracytin
  • Aracytine
  • Beta-Cytosine Arabinoside
  • CHX-3311
  • Cytarabinum
  • Cytarbel
  • Cytosar
  • Cytosine Arabinoside
  • Cytosine-.beta.-arabinoside
  • Cytosine-beta-arabinoside
  • Erpalfa
  • Starasid
  • Tarabine PFS
  • U 19920
  • U-19920
  • Udicil
  • WR-28453

Drug: Etoposide
Given IV
Other Names:
  • Demethyl Epipodophyllotoxin Ethylidine Glucoside
  • EPEG
  • Lastet
  • Toposar
  • Vepesid
  • VP 16
  • VP 16-213
  • VP-16
  • VP-16-213
  • VP16

Drug: Ibrutinib
Given PO
Other Names:
  • BTK Inhibitor PCI-32765
  • CRA-032765
  • Imbruvica
  • PCI-32765

Other: Laboratory Biomarker Analysis
Correlative studies

Drug: Melphalan
Given IV
Other Names:
  • Alanine Nitrogen Mustard
  • CB-3025
  • L-PAM
  • L-Phenylalanine mustard
  • L-Sarcolysin
  • L-Sarcolysin Phenylalanine mustard
  • L-Sarcolysine
  • Melphalanum
  • Phenylalanine Mustard
  • Phenylalanine Nitrogen Mustard
  • Sarcoclorin
  • Sarkolysin
  • WR-19813

Other: Pharmacogenomic Study
Correlative studies
Other Name: PHARMACOGENOMIC

Placebo Comparator: Arm II (placebo, chemotherapy, autoHCT)

CONDITIONING REGIMEN: Patients receive placebo PO on days -6 to -1 and receive 1 of the 2 conditioning regimens as in Arm I.

TRANSPLANT: Patients undergo autologous hematopoietic progenitor cell or bone marrow transplant on day 0.

CONTINUATION REGIMEN: Beginning 30-60 days after transplant, patients receive placebo PO on days 1-28. Treatment repeats every 28 days for 12 cycles in the absence of disease progression or unacceptable toxicity. Patients experiencing disease progression may crossover Arm I.

Procedure: Autologous Bone Marrow Transplantation
Undergo autologous hematopoietic progenitor cells or bone marrow transplant
Other Names:
  • ABMT
  • Autologous Blood and Marrow Transplantation
  • Autologous Bone Marrow Transplant
  • Autologous Marrow Transplantation

Procedure: Autologous Hematopoietic Stem Cell Transplantation
Undergo autologous hematopoietic progenitor cells or bone marrow transplant
Other Names:
  • Autologous Hematopoietic Cell Transplantation
  • autologous stem cell transplantation

Drug: Carmustine
Given IV
Other Names:
  • BCNU
  • Becenum
  • Becenun
  • BiCNU
  • Bis(chloroethyl) Nitrosourea
  • Bis-Chloronitrosourea
  • Carmubris
  • Carmustin
  • Carmustinum
  • FDA 0345
  • N,N''-Bis(2-chloroethyl)-N-nitrosourea
  • Nitrourean
  • Nitrumon
  • SK 27702
  • SRI 1720
  • WR-139021

Drug: Cyclophosphamide
Given IV
Other Names:
  • (-)-Cyclophosphamide
  • 2H-1,3,2-Oxazaphosphorine, 2-[bis(2-chloroethyl)amino]tetrahydro-, 2-oxide, monohydrate
  • Carloxan
  • Ciclofosfamida
  • Ciclofosfamide
  • Cicloxal
  • Clafen
  • Claphene
  • CP monohydrate
  • CTX
  • CYCLO-cell
  • Cycloblastin
  • Cycloblastine
  • Cyclophospham
  • Cyclophosphamid monohydrate
  • Cyclophosphamide Monohydrate
  • Cyclophosphamidum
  • Cyclophosphan
  • Cyclophosphane
  • Cyclophosphanum
  • Cyclostin
  • Cyclostine
  • Cytophosphan
  • Cytophosphane
  • Cytoxan
  • Fosfaseron
  • Genoxal
  • Genuxal
  • Ledoxina
  • Mitoxan
  • Neosar
  • Revimmune
  • Syklofosfamid
  • WR- 138719

Drug: Cytarabine
Given IV
Other Names:
  • .beta.-Cytosine arabinoside
  • 1-.beta.-D-Arabinofuranosyl-4-amino-2(1H)pyrimidinone
  • 1-.beta.-D-Arabinofuranosylcytosine
  • 1-Beta-D-arabinofuranosyl-4-amino-2(1H)pyrimidinone
  • 1-Beta-D-arabinofuranosylcytosine
  • 1.beta.-D-Arabinofuranosylcytosine
  • 2(1H)-Pyrimidinone, 4-Amino-1-beta-D-arabinofuranosyl-
  • 2(1H)-Pyrimidinone, 4-amino-1.beta.-D-arabinofuranosyl-
  • Alexan
  • Ara-C
  • ARA-cell
  • Arabine
  • Arabinofuranosylcytosine
  • Arabinosylcytosine
  • Aracytidine
  • Aracytin
  • Aracytine
  • Beta-Cytosine Arabinoside
  • CHX-3311
  • Cytarabinum
  • Cytarbel
  • Cytosar
  • Cytosine Arabinoside
  • Cytosine-.beta.-arabinoside
  • Cytosine-beta-arabinoside
  • Erpalfa
  • Starasid
  • Tarabine PFS
  • U 19920
  • U-19920
  • Udicil
  • WR-28453

Drug: Etoposide
Given IV
Other Names:
  • Demethyl Epipodophyllotoxin Ethylidine Glucoside
  • EPEG
  • Lastet
  • Toposar
  • Vepesid
  • VP 16
  • VP 16-213
  • VP-16
  • VP-16-213
  • VP16

Other: Laboratory Biomarker Analysis
Correlative studies

Drug: Melphalan
Given IV
Other Names:
  • Alanine Nitrogen Mustard
  • CB-3025
  • L-PAM
  • L-Phenylalanine mustard
  • L-Sarcolysin
  • L-Sarcolysin Phenylalanine mustard
  • L-Sarcolysine
  • Melphalanum
  • Phenylalanine Mustard
  • Phenylalanine Nitrogen Mustard
  • Sarcoclorin
  • Sarkolysin
  • WR-19813

Other: Pharmacogenomic Study
Correlative studies
Other Name: PHARMACOGENOMIC

Other: Placebo
Given PO
Other Names:
  • placebo therapy
  • PLCB
  • sham therapy




Primary Outcome Measures :
  1. 24-month progression-free survival (PFS), defined as the proportion of patients who are alive and progression-free 2 years from randomization [ Time Frame: Time between registration and disease progression or death, whichever comes first, assessed at 24 months ]
    Will be assessed using the Lugano classification.


Secondary Outcome Measures :
  1. Overall survival (OS) [ Time Frame: The time between randomization and death from any cause, assessed up to 5 years (60 months) ]
    For each arm, the distribution of OS will be estimated using the Kaplan-Meier method. OS will be compared between the two arms using the log-rank test and Cox regression method adjusting for the known predictors.

  2. Time to hematopoietic engraftment [ Time Frame: First day of one week without platelet transfusion, assessed up to 5 years ]
    Will be defined as platelet count greater than or equal to 20,000/uL following nadir.

  3. PFS [ Time Frame: Time between registration and disease progression or death, whichever comes first, assessed up to 5 years (60 months) ]
    For each arm, the distribution of PFS will be estimated using the Kaplan-Meier method. PFS will be compared between the two arms using the log-rank test and Cox regression method adjusting for the known predictors.

  4. Response rate using the Lugano classification [ Time Frame: Up to 60 months ]
    The metabolic response proportion following AutoHCT will be compared between the two arms using chi-squared test.

  5. Treatment-related mortality [ Time Frame: Up to 60 months ]
    Treatment-related mortality will be summarized using contingency tables.

  6. Incidence of hematologic toxicity of ibrutinib therapy [ Time Frame: Up to 60 months ]
    Hematologic toxicity will be summarized using contingency tables.

  7. Incidence of secondary malignancies [ Time Frame: Up to 60 months ]
    Incidence of secondary malignancies will be summarized using contingency tables.


Other Outcome Measures:
  1. Fludeoxyglucose positron emission tomography (FDG-PET) imaging results [ Time Frame: Baseline ]
    PFS and OS will be compared between PET/computed tomography (CT) positive and negative groups using the two-sample log-rank test with a 2-sided alpha of 5%. A Cox regression model will be conducted to regress PFS and OS on PET/CT positivity. Deauville criteria analyses will be conducted with cutoffs at scores of 2 and 3, and quantitative measurements, e.g. delta standard uptake value (SUV), %SUV decline and %MTV decline, in place of the dichotomous FDG-PET/CT outcome. Positive/negative predictive values, sensitivity and specificity of PET/CT further estimated by dichotomizing the PFS and OS at 2 years.

  2. GSTT1 null allele expression [ Time Frame: Baseline ]
    GSTT1 null allele expression will be associated with carmustine toxicity. Quantified using the standard Common Terminology Criteria for Adverse Events and changes in diffusing capacity of the lungs for carbon monoxide from baseline.

  3. Single-nuclear polymorphisms (SNPs) in the BCNU metabolism or damage repair pathways [ Time Frame: Baseline ]
    All SNPs will be evaluated for deviation from Hardy-Weinberg. In the absence of a hypothesized effect, analyses will be powered for allele dosing (i.e., additive) effects. The Cochran-Armitage test (for binary endpoints), Jonkheere-Terpstra test (for quantitative traits including biomarker or gene expressions in serum or tumor ribonucleic acid) and the Cox score test (for censored time-to-event outcomes) will be used to quantify marginal associations. Multivariable models, with molecular, clinical and demographic variables, will be constructed using conditional inference trees and random forests.

  4. BCR pathway mutations [ Time Frame: Baseline ]
    The mutation of CD79a/b, caspase recruitment domain family, member 11 (CARD11), tumor necrosis factor, alpha-induced protein 3 TNFAIP3), and myeloid differentiation primary response 88 (MYD88) will be associated with each outcome in the ibrutinib arm (Arm A) using the chi-squared test for response rate and the log-rank test for each censored outcome. Similar analyses will be conducted for the placebo arm (Arm B) to show that the association between mutation and the outcomes observed in the ibrutinib arm is not observed in the placebo arm.

  5. BCL2, MYC, and Ki67 expression in tissue samples by immunohistochemistry (IHC) [ Time Frame: Baseline ]
    The expression of BCL2, MYC, and Ki67 will be analyzed to assess whether they affect clinical outcomes.

  6. MYC translocations [ Time Frame: Baseline ]
    Translocations in MYC with or without BCL2, and BCL6 will be analyzed to determine whether they are related to poor outcomes and whether ibrutinib modifies the prognosis.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • PRE-REGISTRATION ELIGIBILITY CRITERIA (STEP 0)
  • Patients must have paraffin tissue from the diagnostic or relapse biopsy available to be submitted for central pathology review; this review is mandatory prior to registration to confirm eligibility and should be initiated as soon as possible
  • ELIGIBILITY CRITERIA (STEP 1)
  • Diagnosis of World Health Organization (WHO) diffuse large B-cell lymphoma, non-GCB by central review confirmation
  • Patient must be deemed eligible to proceed with high-dose chemotherapy and autologous stem cell transplantation by local transplant center
  • New York Heart Association class I or less; ordinary physical activity does not cause undue fatigue, palpitations, dyspnea, or angina pain; patients 60 years or older must have a left ventricular ejection fraction (LVEF) at rest >= 40% measured by echocardiogram or multi-gated acquisition (MUGA)
  • Diffusion capacity of the lung for carbon monoxide (DLCO) >= 40% of predicted (corrected or uncorrected for hemoglobin per institutional standards)
  • Forced expiratory volume in 1 second (FEV1) >= 40% of predicted (corrected or uncorrected for hemoglobin per institutional standards)
  • Forced vital capacity (FVC) >= 40% of predicted (corrected or uncorrected for hemoglobin per institutional standards)
  • Total bilirubin =< 1.5 x upper limit of normal (ULN) unless isolated hyperbilirubinemia attributed to Gilbert's syndrome
  • Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 3 x upper limit of normal (ULN)
  • Creatinine =< 2.0 mg/dL OR creatinine clearance (calculated clearance permitted) >= 40 mL/min by Cockcroft-Gault formula
  • Prothrombin time (PT)/ international normalized ration (INR) < 1.5 x ULN and partial thromboplastin time (PTT) (activated [a]PTT) < 1.5 x ULN
  • Patient must have progressed or be refractory to prior anthracycline-containing chemotherapy (e.g. rituximab, cyclophosphamide, doxorubicin hydrochloride, vincristine, and prednisone [R-CHOP], dose adjusted etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin, and rituximab [DA-EPOCH-R], etc)
  • No more than 3 prior regimens for large cell component (e.g. one induction and two salvage therapies); monoclonal antibody alone or involved field/involved site radiotherapy do not count as lines of therapy
  • Prior use of ibrutinib is allowed unless patient has had disease progression while receiving ibrutinib
  • Patient must have chemosensitive disease as defined by at least a partial response to salvage therapy at their latest assessment
  • No major surgery =< 7 days prior to registration and no minor surgery =< 3 days prior to registration (with the exception of intravenous access placement, e.g. Hickman or peripherally inserted central catheter [PICC])
  • Not pregnant and not nursing, because this study involves an agent that has known genotoxic, mutagenic and teratogenic effects; therefore, for women of childbearing potential only, a negative serum pregnancy test must be obtained within 14 days prior to registration

    • Women of childbearing potential must use adequate contraception from study start to one month after the last dose of protocol therapy; adequate contraception is defined as hormonal birth control, intrauterine device, double barrier method or total abstinence; men must practice complete abstinence or agree to use an adequate contraception method from study start to one month after the last dose of protocol therapy
  • Patients should not require chronic use of strong CYP3A inhibitors or strong CYP3A inducers
  • Patients should not require concurrent therapeutic doses of steroids (> 20 mg of prednisone/day or equivalent) unless they need them for the indications; steroids should be discontinued for 14 days before starting protocol treatment
  • Human immunodeficiency virus (HIV) infected patients are eligible provided they meet all other eligibility criteria, and:

    • There is no prior history of acquired immunodeficiency syndrome (AIDS) defining conditions other than historically low CD4+ T-cell count or B-cell lymphoma
    • In the opinion of an expert in HIV disease, prospects for long-term survival are excellent were it not for the diagnosis of lymphoma
    • Use of HIV protease inhibitors as part of the anti-HIV regimen OR as a pharmacologic booster is not allowed
    • Zidovudine is not allowed
    • Once daily combination pills for HIV containing a pharmacologic booster such as cobicistat are not allowed
    • Patients with multi-drug resistant HIV are not eligible
  • Patients cannot have:

    • Active central nervous system or meningeal involvement by lymphoma; patients with a history of central nervous system (CNS) or meningeal involvement must be in a documented remission by cerebrospinal fluid (CSF) evaluation and contrast-enhanced magnetic resonance imaging (MRI) imaging for at least 91 days prior to registration
    • Evidence of myelodysplasia or cytogenetic abnormality indicative of myelodysplasia on any bone marrow biopsy prior to initiation of therapy
    • A known bleeding diathesis
    • Requirement for warfarin or similar vitamin K antagonists; these drugs are prohibited 28 days prior to the first treatment and throughout the trial
    • History of stroke or intracranial hemorrhage =< 6 months before treatment
    • Currently active, clinically significant hepatic impairment (Child-Pugh class B or C according to the Child Pugh classification
    • History of allergic reactions attributed to compounds of similar chemical or biologic composition to ibrutinib or other agents used in study
    • Serologic status reflecting active hepatitis B or C infection; patients that are positive for hepatitis B core antibody, hepatitis B surface antigen (HBsAg), or hepatitis C antibody must have a negative polymerase chain reaction (PCR) prior to enrollment; (PCR positive patients will be excluded)
  • Eastern Cooperative Oncology Group (ECOG) performance status must be =< 2

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02443077


  Hide Study Locations
Locations
Layout table for location information
United States, Alaska
Anchorage Associates in Radiation Medicine Suspended
Anchorage, Alaska, United States, 98508
Anchorage Radiation Therapy Center Suspended
Anchorage, Alaska, United States, 99504
Alaska Breast Care and Surgery LLC Suspended
Anchorage, Alaska, United States, 99508
Alaska Oncology and Hematology LLC Suspended
Anchorage, Alaska, United States, 99508
Alaska Women's Cancer Care Suspended
Anchorage, Alaska, United States, 99508
Anchorage Oncology Centre Suspended
Anchorage, Alaska, United States, 99508
Katmai Oncology Group Suspended
Anchorage, Alaska, United States, 99508
Providence Alaska Medical Center Suspended
Anchorage, Alaska, United States, 99508
United States, Arizona
Banner University Medical Center - Tucson Recruiting
Tucson, Arizona, United States, 85719
Contact: Site Public Contact       aselegue@email.arizona.edu   
Principal Investigator: Keri R. Maher         
University of Arizona Cancer Center-North Campus Recruiting
Tucson, Arizona, United States, 85719
Contact: Site Public Contact    800-327-2873      
Principal Investigator: Keri R. Maher         
United States, California
Providence Saint Joseph Medical Center/Disney Family Cancer Center Suspended
Burbank, California, United States, 91505
City of Hope Comprehensive Cancer Center Suspended
Duarte, California, United States, 91010
UC San Diego Moores Cancer Center Suspended
La Jolla, California, United States, 92093
Loma Linda University Medical Center Suspended
Loma Linda, California, United States, 92354
University of California Davis Comprehensive Cancer Center Active, not recruiting
Sacramento, California, United States, 95817
UCSF Medical Center-Parnassus Recruiting
San Francisco, California, United States, 94143
Contact: Site Public Contact    877-827-3222      
Principal Investigator: Charalambos Andreadis         
United States, Colorado
Rocky Mountain Cancer Centers-Aurora Recruiting
Aurora, Colorado, United States, 80012
Contact: Site Public Contact    303-777-2663    ccrp@co-cancerresearch.org   
Principal Investigator: Keren Sturtz         
The Medical Center of Aurora Suspended
Aurora, Colorado, United States, 80012
University of Colorado Hospital Suspended
Aurora, Colorado, United States, 80045
Boulder Community Hospital Recruiting
Boulder, Colorado, United States, 80301
Contact: Site Public Contact    303-777-2663    jbloomfield@co-cancerresearch.org   
Principal Investigator: Keren Sturtz         
Rocky Mountain Cancer Centers-Boulder Recruiting
Boulder, Colorado, United States, 80304
Contact: Site Public Contact    303-777-2663    ccrp@co-cancerresearch.org   
Principal Investigator: Keren Sturtz         
UCHealth Memorial Hospital Central Active, not recruiting
Colorado Springs, Colorado, United States, 80909
Denver Health Medical Center Suspended
Denver, Colorado, United States, 80204
National Jewish Health-Main Campus Recruiting
Denver, Colorado, United States, 80206
Contact: Site Public Contact    877-225-5654    glicht@co-cancerresearch.org   
Principal Investigator: Keren Sturtz         
The Women's Imaging Center Suspended
Denver, Colorado, United States, 80209
Colorado Blood Cancer Institute Recruiting
Denver, Colorado, United States, 80218
Contact: Site Public Contact    303-777-2663    ccrp@co-cancerresearch.org   
Principal Investigator: Keren Sturtz         
Presbyterian - Saint Lukes Medical Center - Health One Suspended
Denver, Colorado, United States, 80218
Rocky Mountain Cancer Centers-Midtown Recruiting
Denver, Colorado, United States, 80218
Contact: Site Public Contact    303-777-2663    ccrp@co-cancerresearch.org   
Principal Investigator: Keren Sturtz         
SCL Health Saint Joseph Hospital Recruiting
Denver, Colorado, United States, 80218
Contact: Site Public Contact    303-777-2663    ccrp@co-cancerresearch.org   
Principal Investigator: Keren Sturtz         
Rocky Mountain Cancer Centers-Rose Recruiting
Denver, Colorado, United States, 80220
Contact: Site Public Contact    303-777-2663    ccrp@co-cancerresearch.org   
Principal Investigator: Keren Sturtz         
Mountain Blue Cancer Care Center - Swedish Recruiting
Englewood, Colorado, United States, 80113
Contact: Site Public Contact    303-777-2663    WSCR@westernstatesncorp.org   
Principal Investigator: Keren Sturtz         
Swedish Medical Center Recruiting
Englewood, Colorado, United States, 80113
Contact: Site Public Contact    303-777-2663    ccrp@co-cancerresearch.org   
Principal Investigator: Keren Sturtz         
Poudre Valley Hospital Recruiting
Fort Collins, Colorado, United States, 80524
Contact: Site Public Contact    970-297-6150      
Principal Investigator: Manali K. Kamdar         
National Jewish Health-Western Hematology Oncology Suspended
Golden, Colorado, United States, 80401
Saint Mary's Hospital and Regional Medical Center Recruiting
Grand Junction, Colorado, United States, 81501
Contact: Site Public Contact    303-777-2663    ccrp@co-cancerresearch.org   
Principal Investigator: Keren Sturtz         
Grand Valley Oncology Active, not recruiting
Grand Junction, Colorado, United States, 81505
North Colorado Medical Center Suspended
Greeley, Colorado, United States, 80631
Good Samaritan Medical Center Suspended
Lafayette, Colorado, United States, 80026
Rocky Mountain Cancer Centers-Littleton Recruiting
Littleton, Colorado, United States, 80120
Contact: Site Public Contact    303-777-2663    ccrp@co-cancerresearch.org   
Principal Investigator: Keren Sturtz         
Rocky Mountain Cancer Centers-Sky Ridge Recruiting
Lone Tree, Colorado, United States, 80124
Contact: Site Public Contact    303-777-2663    ccrp@co-cancerresearch.org   
Principal Investigator: Keren Sturtz         
McKee Medical Center Recruiting
Loveland, Colorado, United States, 80539
Contact: Site Public Contact    303-777-2663    ccrp@co-cancerresearch.org   
Principal Investigator: Keren Sturtz         
SCL Health Lutheran Medical Center Recruiting
Wheat Ridge, Colorado, United States, 80033
Contact: Site Public Contact    303-777-2663    ccrp@co-cancerresearch.org   
Principal Investigator: Keren Sturtz         
United States, Connecticut
Yale University Suspended
New Haven, Connecticut, United States, 06520
United States, Delaware
Beebe Medical Center Suspended
Lewes, Delaware, United States, 19958
Delaware Clinical and Laboratory Physicians PA Suspended
Newark, Delaware, United States, 19713
Helen F Graham Cancer Center Suspended
Newark, Delaware, United States, 19713
Medical Oncology Hematology Consultants PA Recruiting
Newark, Delaware, United States, 19713
Contact: Site Public Contact    302-623-4450    KDempsey@christianacare.org   
Principal Investigator: Gregory A. Masters         
Christiana Care Health System-Christiana Hospital Suspended
Newark, Delaware, United States, 19718
Beebe Health Campus Suspended
Rehoboth Beach, Delaware, United States, 19971
Nanticoke Memorial Hospital Suspended
Seaford, Delaware, United States, 19973
Christiana Care Health System-Wilmington Hospital Suspended
Wilmington, Delaware, United States, 19801
United States, Florida
UM Sylvester Comprehensive Cancer Center at Deerfield Beach Suspended
Deerfield Beach, Florida, United States, 33442
University of Florida Health Science Center - Gainesville Recruiting
Gainesville, Florida, United States, 32610
Contact: Site Public Contact    352-273-8010    cancer-center@ufl.edu   
Principal Investigator: John R. Wingard         
University of Miami Miller School of Medicine-Sylvester Cancer Center Suspended
Miami, Florida, United States, 33136
Moffitt Cancer Center Recruiting
Tampa, Florida, United States, 33612
Contact: Site Public Contact    800-679-0775    canceranswers@moffitt.org   
Principal Investigator: Farhad Khimani         
United States, Georgia
Emory University Hospital/Winship Cancer Institute Suspended
Atlanta, Georgia, United States, 30322
Northside Hospital Recruiting
Atlanta, Georgia, United States, 30342
Contact: Site Public Contact    404-303-3355    ClinicalTrials@northside.com   
Principal Investigator: Henry K. Holland         
Augusta University Medical Center Recruiting
Augusta, Georgia, United States, 30912
Contact: Site Public Contact    706-721-2388    ga_cares@augusta.edu   
Principal Investigator: Sharad A. Ghamande         
United States, Idaho
Saint Alphonsus Cancer Care Center-Boise Recruiting
Boise, Idaho, United States, 83706
Contact: Site Public Contact    734-712-3671    stephanie.couch@stjoeshealth.org   
Principal Investigator: John M. Schallenkamp         
Saint Luke's Mountain States Tumor Institute Recruiting
Boise, Idaho, United States, 83712
Contact: Site Public Contact    208-381-2774    eslinget@slhs.org   
Principal Investigator: Alison K. Conlin         
Saint Alphonsus Cancer Care Center-Caldwell Recruiting
Caldwell, Idaho, United States, 83605
Contact: Site Public Contact    734-712-3671    stephanie.couch@stjoeshealth.org   
Principal Investigator: John M. Schallenkamp         
Kootenai Medical Center Recruiting
Coeur d'Alene, Idaho, United States, 83814
Contact: Site Public Contact    406-969-6060    mccinfo@mtcancer.org   
Principal Investigator: John M. Schallenkamp         
Saint Luke's Mountain States Tumor Institute - Fruitland Recruiting
Fruitland, Idaho, United States, 83619
Contact: Site Public Contact    208-381-8059    hallsc@slhs.org   
Principal Investigator: Alison K. Conlin         
Saint Luke's Mountain States Tumor Institute - Meridian Recruiting
Meridian, Idaho, United States, 83642
Contact: Site Public Contact    208-381-8059    hallsc@slhs.org   
Principal Investigator: Alison K. Conlin         
Saint Alphonsus Medical Center-Nampa Recruiting
Nampa, Idaho, United States, 83686
Contact: Site Public Contact    734-712-3671    stephanie.couch@stjoeshealth.org   
Principal Investigator: John M. Schallenkamp         
Saint Luke's Mountain States Tumor Institute - Nampa Recruiting
Nampa, Idaho, United States, 83686
Contact: Site Public Contact    208-381-8059    hallsc@slhs.org   
Principal Investigator: Alison K. Conlin         
Kootenai Cancer Center Recruiting
Post Falls, Idaho, United States, 83854
Contact: Site Public Contact    406-969-6060    mccinfo@mtcancer.org   
Principal Investigator: John M. Schallenkamp         
Kootenai Cancer Clinic Recruiting
Sandpoint, Idaho, United States, 83864
Contact: Site Public Contact    406-969-6060    mccinfo@mtcancer.org   
Principal Investigator: John M. Schallenkamp         
Saint Luke's Mountain States Tumor Institute-Twin Falls Recruiting
Twin Falls, Idaho, United States, 83301
Contact: Site Public Contact    208-381-8059    hallsc@slhs.org   
Principal Investigator: Alison K. Conlin         
United States, Illinois
Rush University Medical Center Recruiting
Chicago, Illinois, United States, 60612
Contact: Site Public Contact    312-942-5498    clinical_trials@rush.edu   
Principal Investigator: Sunita Nathan         
University of Illinois Recruiting
Chicago, Illinois, United States, 60612
Contact: Site Public Contact    312-355-3046      
Principal Investigator: Pritesh Patel         
University of Chicago Comprehensive Cancer Center Recruiting
Chicago, Illinois, United States, 60637
Contact: Site Public Contact    773-702-8222    cancerclinicaltrials@bsd.uchicago.edu   
Principal Investigator: Peter Riedell         
Loyola University Medical Center Suspended
Maywood, Illinois, United States, 60153
UC Comprehensive Cancer Center at Silver Cross Suspended
New Lenox, Illinois, United States, 60451
United States, Kansas
Cancer Center of Kansas - Chanute Active, not recruiting
Chanute, Kansas, United States, 66720
Cancer Center of Kansas - Dodge City Active, not recruiting
Dodge City, Kansas, United States, 67801
Cancer Center of Kansas - El Dorado Active, not recruiting
El Dorado, Kansas, United States, 67042
Cancer Center of Kansas - Fort Scott Active, not recruiting
Fort Scott, Kansas, United States, 66701
Cancer Center of Kansas-Independence Active, not recruiting
Independence, Kansas, United States, 67301
University of Kansas Cancer Center Recruiting
Kansas City, Kansas, United States, 66160
Contact: Site Public Contact    913-945-7552    ctnursenav@kumc.edu   
Principal Investigator: Siddhartha Ganguly         
Cancer Center of Kansas-Kingman Active, not recruiting
Kingman, Kansas, United States, 67068
Lawrence Memorial Hospital Recruiting
Lawrence, Kansas, United States, 66044
Contact: Site Public Contact    316-268-5374    Keisha.humphries@ascension.org   
Principal Investigator: Shaker R. Dakhil         
Cancer Center of Kansas-Liberal Active, not recruiting
Liberal, Kansas, United States, 67905
Cancer Center of Kansas-Manhattan Active, not recruiting
Manhattan, Kansas, United States, 66502
Cancer Center of Kansas - McPherson Active, not recruiting
McPherson, Kansas, United States, 67460
Cancer Center of Kansas - Newton Active, not recruiting
Newton, Kansas, United States, 67114
Cancer Center of Kansas - Parsons Active, not recruiting
Parsons, Kansas, United States, 67357
Cancer Center of Kansas - Pratt Active, not recruiting
Pratt, Kansas, United States, 67124
Cancer Center of Kansas - Salina Active, not recruiting
Salina, Kansas, United States, 67401
Cancer Center of Kansas - Wellington Active, not recruiting
Wellington, Kansas, United States, 67152
University of Kansas Hospital-Westwood Cancer Center Recruiting
Westwood, Kansas, United States, 66205
Contact: Site Public Contact    913-945-7552    ctnursenav@kumc.edu   
Principal Investigator: Siddhartha Ganguly         
Associates In Womens Health Active, not recruiting
Wichita, Kansas, United States, 67208
Cancer Center of Kansas-Wichita Medical Arts Tower Recruiting
Wichita, Kansas, United States, 67208
Contact: Site Public Contact    316-268-5374    Keisha.humphries@ascension.org   
Principal Investigator: Shaker R. Dakhil         
Ascension Via Christi Hospitals Wichita Recruiting
Wichita, Kansas, United States, 67214
Contact: Site Public Contact    800-362-0070    Keisha.humphries@ascension.org   
Principal Investigator: Shaker R. Dakhil         
Cancer Center of Kansas - Wichita Recruiting
Wichita, Kansas, United States, 67214
Contact: Site Public Contact    316-268-5374    Keisha.humphries@ascension.org   
Principal Investigator: Shaker R. Dakhil         
Cancer Center of Kansas - Winfield Active, not recruiting
Winfield, Kansas, United States, 67156
United States, Kentucky
The James Graham Brown Cancer Center at University of Louisville Recruiting
Louisville, Kentucky, United States, 40202
Contact: Site Public Contact    502-562-3429      
Principal Investigator: Robert V. Emmons         
United States, Louisiana
Baton Rouge General Medical Center Suspended
Baton Rouge, Louisiana, United States, 70806
Hematology/Oncology Clinic LLP Suspended
Baton Rouge, Louisiana, United States, 70809
Tulane University Health Sciences Center Recruiting
New Orleans, Louisiana, United States, 70112
Contact: Site Public Contact    504-988-6121      
Principal Investigator: Hana F. Safah         
Ochsner Medical Center Jefferson Recruiting
New Orleans, Louisiana, United States, 70121
Contact: Site Public Contact    504-703-8712    Gregory.Johnstone@ochsner.org   
Principal Investigator: Andrew P. Dalovisio         
United States, Maryland
Johns Hopkins University/Sidney Kimmel Cancer Center Active, not recruiting
Baltimore, Maryland, United States, 21287
United States, Massachusetts
Simonds-Sinon Regional Cancer Center Active, not recruiting
Fitchburg, Massachusetts, United States, 01420
UMass Memorial Medical Center - University Campus Recruiting
Worcester, Massachusetts, United States, 01655
Contact: Site Public Contact    508-856-3216    cancer.research@umassmed.edu   
Principal Investigator: Jan Cerny         
United States, Michigan
University of Michigan Comprehensive Cancer Center Recruiting
Ann Arbor, Michigan, United States, 48109
Contact: Site Public Contact    800-865-1125      
Principal Investigator: Attaphol Pawarode         
Bronson Battle Creek Suspended
Battle Creek, Michigan, United States, 49017
Wayne State University/Karmanos Cancer Institute Suspended
Detroit, Michigan, United States, 48201
Mercy Health Saint Mary's Suspended
Grand Rapids, Michigan, United States, 49503
Spectrum Health at Butterworth Campus Recruiting
Grand Rapids, Michigan, United States, 49503
Contact: Site Public Contact    616-391-1230    crcwm-regulatory@crcwm.org   
Principal Investigator: Kathleen J. Yost         
Bronson Methodist Hospital Suspended
Kalamazoo, Michigan, United States, 49007
West Michigan Cancer Center Recruiting
Kalamazoo, Michigan, United States, 49007
Contact: Site Public Contact    616-391-1230    crcwm-regulatory@crcwm.org   
Principal Investigator: Kathleen J. Yost         
Borgess Medical Center Suspended
Kalamazoo, Michigan, United States, 49048
Mercy Health Mercy Campus Recruiting
Muskegon, Michigan, United States, 49444
Contact: Site Public Contact    616-391-1230    crcwm-regulatory@crcwm.org   
Principal Investigator: Kathleen J. Yost         
Lakeland Hospital Niles Suspended
Niles, Michigan, United States, 49120
Cancer and Hematology Centers of Western Michigan - Norton Shores Recruiting
Norton Shores, Michigan, United States, 49444
Contact: Site Public Contact    616-391-1230    connie.szczepanek@crcwm.org   
Principal Investigator: Kathleen J. Yost         
Spectrum Health Reed City Hospital Recruiting
Reed City, Michigan, United States, 49677
Contact: Site Public Contact    616-391-1230    crcwm-regulatory@crcwm.org   
Principal Investigator: Kathleen J. Yost         
Lakeland Medical Center Saint Joseph Suspended
Saint Joseph, Michigan, United States, 49085
Marie Yeager Cancer Center Suspended
Saint Joseph, Michigan, United States, 49085
Munson Medical Center Recruiting
Traverse City, Michigan, United States, 49684
Contact: Site Public Contact    616-391-1230    crcwm-regulatory@crcwm.org   
Principal Investigator: Kathleen J. Yost         
Metro Health Hospital Suspended
Wyoming, Michigan, United States, 49519
United States, Minnesota
University of Minnesota/Masonic Cancer Center Recruiting
Minneapolis, Minnesota, United States, 55455
Contact: Site Public Contact    612-624-2620      
Principal Investigator: Veronika Bachanova         
Mayo Clinic Recruiting
Rochester, Minnesota, United States, 55905
Contact: Site Public Contact    855-776-0015      
Principal Investigator: Patrick B. Johnston         
United States, Missouri
Siteman Cancer Center at West County Hospital Recruiting
Creve Coeur, Missouri, United States, 63141
Contact: Site Public Contact    800-600-3606    info@siteman.wustl.edu   
Principal Investigator: Amanda F. Cashen         
Washington University School of Medicine Recruiting
Saint Louis, Missouri, United States, 63110
Contact: Site Public Contact    800-600-3606    info@siteman.wustl.edu   
Principal Investigator: Amanda F. Cashen         
Siteman Cancer Center-South County Recruiting
Saint Louis, Missouri, United States, 63129
Contact: Site Public Contact    800-600-3606    info@siteman.wustl.edu   
Principal Investigator: Amanda F. Cashen         
United States, Montana
Community Hospital of Anaconda Suspended
Anaconda, Montana, United States, 59711
Billings Clinic Cancer Center Recruiting
Billings, Montana, United States, 59101
Contact: Site Public Contact    800-996-2663    research@billingsclinic.org   
Principal Investigator: John M. Schallenkamp         
Saint Vincent Healthcare Suspended
Billings, Montana, United States, 59101
Saint Vincent Frontier Cancer Center Suspended
Billings, Montana, United States, 59102
Bozeman Deaconess Hospital Recruiting
Bozeman, Montana, United States, 59715
Contact: Site Public Contact    406-969-6060    mccinfo@mtcancer.org   
Principal Investigator: John M. Schallenkamp         
Benefis Healthcare- Sletten Cancer Institute Recruiting
Great Falls, Montana, United States, 59405
Contact: Site Public Contact    406-969-6060    mccinfo@mtcancer.org   
Principal Investigator: John M. Schallenkamp         
Great Falls Clinic Suspended
Great Falls, Montana, United States, 59405
Saint Peter's Community Hospital Suspended
Helena, Montana, United States, 59601
Kalispell Regional Medical Center Recruiting
Kalispell, Montana, United States, 59901
Contact: Site Public Contact    406-969-6060    mccinfo@mtcancer.org   
Principal Investigator: John M. Schallenkamp         
Saint Patrick Hospital - Community Hospital Suspended
Missoula, Montana, United States, 59802
Community Medical Hospital Recruiting
Missoula, Montana, United States, 59804
Contact: Site Public Contact    406-969-6060    mccinfo@mtcancer.org   
Principal Investigator: John M. Schallenkamp         
United States, Nebraska
Nebraska Medicine-Bellevue Recruiting
Bellevue, Nebraska, United States, 68123
Contact: Site Public Contact    402-559-6941    unmcrsa@unmc.edu   
Principal Investigator: Julie M. Vose         
Nebraska Medicine-Village Pointe Recruiting
Omaha, Nebraska, United States, 68118
Contact: Site Public Contact    402-559-5600      
Principal Investigator: Julie M. Vose         
University of Nebraska Medical Center Recruiting
Omaha, Nebraska, United States, 68198
Contact: Site Public Contact    402-559-6941    unmcrsa@unmc.edu   
Principal Investigator: Julie M. Vose         
United States, New Hampshire
Dartmouth Hitchcock Medical Center Recruiting
Lebanon, New Hampshire, United States, 03756
Contact: Site Public Contact    800-639-6918    cancer.research.nurse@dartmouth.edu   
Principal Investigator: Christopher H. Lowrey         
United States, New York
Montefiore Medical Center-Einstein Campus Suspended
Bronx, New York, United States, 10461
Montefiore Medical Center-Weiler Hospital Suspended
Bronx, New York, United States, 10461
Children's Hospital at Montefiore Suspended
Bronx, New York, United States, 10467
Montefiore Medical Center - Moses Campus Suspended
Bronx, New York, United States, 10467
Roswell Park Cancer Institute Recruiting
Buffalo, New York, United States, 14263
Contact: Site Public Contact    800-767-9355    askroswell@roswellpark.org   
Principal Investigator: Philip L. McCarthy         
NYP/Weill Cornell Medical Center Recruiting
New York, New York, United States, 10065
Contact: Site Public Contact    212-746-1848      
Principal Investigator: Adrienne A. Phillips         
University of Rochester Suspended
Rochester, New York, United States, 14642
State University of New York Upstate Medical University Recruiting
Syracuse, New York, United States, 13210
Contact: Site Public Contact    315-464-5476      
Principal Investigator: Teresa C. Gentile         
United States, North Carolina
UNC Lineberger Comprehensive Cancer Center Suspended
Chapel Hill, North Carolina, United States, 27599
Duke University Medical Center Recruiting
Durham, North Carolina, United States, 27710
Contact: Site Public Contact    888-275-3853      
Principal Investigator: Jeffrey Crawford         
Wake Forest University Health Sciences Recruiting
Winston-Salem, North Carolina, United States, 27157
Contact: Site Public Contact    336-713-6771      
Principal Investigator: Rakhee Vaidya         
United States, Ohio
University of Cincinnati/Barrett Cancer Center Recruiting
Cincinnati, Ohio, United States, 45219
Contact: Site Public Contact    513-558-4553    uchealthnews@uc.edu   
Principal Investigator: Tahir Latif         
Case Western Reserve University Recruiting
Cleveland, Ohio, United States, 44106
Contact: Site Public Contact    800-641-2422    CTUReferral@UHhospitals.org   
Principal Investigator: Paolo F. Caimi         
Cleveland Clinic Foundation Recruiting
Cleveland, Ohio, United States, 44195
Contact: Site Public Contact    866-223-8100    CancerAnswer@ccf.org   
Principal Investigator: Aaron T. Gerds         
Ohio State University Comprehensive Cancer Center Recruiting
Columbus, Ohio, United States, 43210
Contact: Site Public Contact    800-293-5066    Jamesline@osumc.edu   
Principal Investigator: Samantha M. Jaglowski         
University Pointe Recruiting
West Chester, Ohio, United States, 45069
Contact: Site Public Contact       clinicaltrials@ucphysicians.com   
Principal Investigator: Tahir Latif         
United States, Oklahoma
University of Oklahoma Health Sciences Center Recruiting
Oklahoma City, Oklahoma, United States, 73104
Contact: Site Public Contact    405-271-8777    ou-clinical-trials@ouhsc.edu   
Principal Investigator: George B. Selby         
United States, Oregon
Saint Charles Health System Suspended
Bend, Oregon, United States, 97701
Clackamas Radiation Oncology Center Suspended
Clackamas, Oregon, United States, 97015
Providence Oncology and Hematology Care Southeast Recruiting
Clackamas, Oregon, United States, 97015
Contact: Site Public Contact    503-215-2614    CanRsrchStudies@providence.org   
Principal Investigator: Alison K. Conlin         
Bay Area Hospital Suspended
Coos Bay, Oregon, United States, 97420
Providence Newberg Medical Center Suspended
Newberg, Oregon, United States, 97132
Saint Alphonsus Medical Center-Ontario Recruiting
Ontario, Oregon, United States, 97914
Contact: Site Public Contact    734-712-3671    stephanie.couch@stjoeshealth.org   
Principal Investigator: John M. Schallenkamp         
Providence Willamette Falls Medical Center Suspended
Oregon City, Oregon, United States, 97045
Legacy Good Samaritan Hospital and Medical Center Suspended
Portland, Oregon, United States, 97210
Providence Portland Medical Center Recruiting
Portland, Oregon, United States, 97213
Contact: Site Public Contact    503-215-2614    CanRsrchStudies@providence.org   
Principal Investigator: Alison K. Conlin         
Providence Saint Vincent Medical Center Recruiting
Portland, Oregon, United States, 97225
Contact: Site Public Contact    503-215-2614    CanRsrchStudies@providence.org   
Principal Investigator: Alison K. Conlin         
Oregon Health and Science University Recruiting
Portland, Oregon, United States, 97239
Contact: Site Public Contact    503-494-1080    trials@ohsu.edu   
Principal Investigator: Sarah J. Nagle         
United States, Pennsylvania
Christiana Care Health System-Concord Health Center Suspended
Chadds Ford, Pennsylvania, United States, 19317
Geisinger Medical Center Recruiting
Danville, Pennsylvania, United States, 17822
Contact: Site Public Contact    570-271-5251    HemonCCTrials@geisinger.edu   
Principal Investigator: Joseph J. Vadakara         
Geisinger Medical Center-Cancer Center Hazleton Recruiting
Hazleton, Pennsylvania, United States, 18201
Contact: Site Public Contact    570-459-2901    HemonCCTrials@geisinger.edu   
Principal Investigator: Joseph J. Vadakara         
Geisinger Medical Oncology-Lewisburg Recruiting
Lewisburg, Pennsylvania, United States, 17837
Contact: Site Public Contact    570-374-8555    HemonCCTrials@geisinger.edu   
Principal Investigator: Joseph J. Vadakara         
Lewistown Hospital Recruiting
Lewistown, Pennsylvania, United States, 17044
Contact: Site Public Contact    717-242-7703    HemonCCTrials@geisinger.edu   
Principal Investigator: Joseph J. Vadakara         
Fox Chase Cancer Center Recruiting
Philadelphia, Pennsylvania, United States, 19111
Contact: Site Public Contact    215-728-4790      
Principal Investigator: Henry C. Fung         
University of Pittsburgh Cancer Institute (UPCI) Active, not recruiting
Pittsburgh, Pennsylvania, United States, 15232
Geisinger Cancer Services-Pottsville Recruiting
Pottsville, Pennsylvania, United States, 17901
Contact: Site Public Contact    800-275-6401    HemonCCTrials@geisinger.edu   
Principal Investigator: Joseph J. Vadakara         
Community Medical Center Recruiting
Scranton, Pennsylvania, United States, 18510
Contact: Site Public Contact    570-703-4768    HemonCCTrials@geisinger.edu   
Principal Investigator: Joseph J. Vadakara         
Geisinger Medical Oncology-Selinsgrove Suspended
Selinsgrove, Pennsylvania, United States, 17870
Geisinger Medical Group Recruiting
State College, Pennsylvania, United States, 16801
Contact: Site Public Contact    570-271-5251    HemonCCTrials@geisinger.edu   
Principal Investigator: Joseph J. Vadakara         
Geisinger Wyoming Valley/Henry Cancer Center Recruiting
Wilkes-Barre, Pennsylvania, United States, 18711
Contact: Site Public Contact    570-271-5251    HemonCCTrials@geisinger.edu   
Principal Investigator: Joseph J. Vadakara         
United States, South Carolina
Medical University of South Carolina Recruiting
Charleston, South Carolina, United States, 29425
Contact: Site Public Contact    843-792-9321    hcc-clinical-trials@musc.edu   
Principal Investigator: Brian T. Hess         
Prisma Health Cancer Institute - Laurens Suspended
Clinton, South Carolina, United States, 29325
Prisma Health Cancer Institute - Easley Recruiting
Easley, South Carolina, United States, 29640
Contact: Site Public Contact    864-522-2066    kim.williams3@prismahealth.org   
Principal Investigator: Jeffrey K. Giguere         
Saint Francis Hospital Recruiting
Greenville, South Carolina, United States, 29601
Contact: Site Public Contact    864-603-6213    meissa_beckman@bshsi.org   
Principal Investigator: Robert D. Siegel         
Prisma Health Cancer Institute - Butternut Recruiting
Greenville, South Carolina, United States, 29605
Contact: Site Public Contact    864-522-2066    kim.williams3@prismahealth.org   
Principal Investigator: Jeffrey K. Giguere         
Prisma Health Cancer Institute - Faris Recruiting
Greenville, South Carolina, United States, 29605
Contact: Site Public Contact    864-522-2066    kim.williams3@prismahealth.org   
Principal Investigator: Jeffrey K. Giguere         
Prisma Health Greenville Memorial Hospital Suspended
Greenville, South Carolina, United States, 29605
Saint Francis Cancer Center Recruiting
Greenville, South Carolina, United States, 29607
Contact: Site Public Contact    864-603-6213    meissa_beckman@bshsi.org   
Principal Investigator: Robert D. Siegel         
Prisma Health Cancer Institute - Eastside Recruiting
Greenville, South Carolina, United States, 29615
Contact: Site Public Contact    864-522-2066    kim.williams3@prismahealth.org   
Principal Investigator: Jeffrey K. Giguere         
Prisma Health Cancer Institute - Greer Recruiting
Greer, South Carolina, United States, 29650
Contact: Site Public Contact    864-522-2066    kim.williams3@prismahealth.org   
Principal Investigator: Jeffrey K. Giguere         
Prisma Health Cancer Institute - Seneca Recruiting
Seneca, South Carolina, United States, 29672
Contact: Site Public Contact    864-522-2066    kim.williams3@prismahealth.org   
Principal Investigator: Jeffrey K. Giguere         
Prisma Health Cancer Institute - Spartanburg Recruiting
Spartanburg, South Carolina, United States, 29307
Contact: Site Public Contact    864-522-2066    kim.williams3@prismahealth.org   
Principal Investigator: Jeffrey K. Giguere         
United States, South Dakota
Avera Cancer Institute Active, not recruiting
Sioux Falls, South Dakota, United States, 57105
United States, Tennessee
Vanderbilt-Ingram Cancer Center Cool Springs Active, not recruiting
Franklin, Tennessee, United States, 37067
Baptist Memorial Hospital and Cancer Center-Memphis Recruiting
Memphis, Tennessee, United States, 38120
Contact: Site Public Contact    901-226-1366    BCCclintrials@bmhcc.org   
Principal Investigator: Muhammad Raza         
Vanderbilt Breast Center at One Hundred Oaks Active, not recruiting
Nashville, Tennessee, United States, 37204
Vanderbilt University/Ingram Cancer Center Active, not recruiting
Nashville, Tennessee, United States, 37232
United States, Texas
Baylor College of Medicine/Dan L Duncan Comprehensive Cancer Center Recruiting
Houston, Texas, United States, 77030
Contact: Site Public Contact    713-798-1354    burton@bcm.edu   
Principal Investigator: George Carrum         
United States, Utah
American Fork Hospital / Huntsman Intermountain Cancer Center Suspended
American Fork, Utah, United States, 84003
Sandra L Maxwell Cancer Center Suspended
Cedar City, Utah, United States, 84720
Farmington Health Center Suspended
Farmington, Utah, United States, 84025
Logan Regional Hospital Suspended
Logan, Utah, United States, 84321
Intermountain Medical Center Suspended
Murray, Utah, United States, 84107
McKay-Dee Hospital Center Suspended
Ogden, Utah, United States, 84403
Utah Valley Regional Medical Center Suspended
Provo, Utah, United States, 84604
Riverton Hospital Suspended
Riverton, Utah, United States, 84065
Dixie Medical Center Regional Cancer Center Suspended
Saint George, Utah, United States, 84770
Utah Cancer Specialists-Salt Lake City Suspended
Salt Lake City, Utah, United States, 84106
Huntsman Cancer Institute/University of Utah Recruiting
Salt Lake City, Utah, United States, 84112
Contact: Site Public Contact    888-424-2100    cancerinfo@hci.utah.edu   
Principal Investigator: Catherine J. Lee         
LDS Hospital Recruiting
Salt Lake City, Utah, United States, 84143
Contact: Site Public Contact    801-408-1347    officeofresearch@imail.org   
Principal Investigator: Birgitta H. Mitchell         
South Jordan Health Center Suspended
South Jordan, Utah, United States, 84009
United States, Virginia
University of Virginia Cancer Center Recruiting
Charlottesville, Virginia, United States, 22908
Contact: Site Public Contact    434-243-6303    PAS9E@virginia.edu   
Principal Investigator: Karen K. Ballen         
Virginia Commonwealth University/Massey Cancer Center Recruiting
Richmond, Virginia, United States, 23298
Contact: Site Public Contact    804-628-1914    klcampbell@vcu.edu   
Principal Investigator: John M. McCarty         
United States, Washington
Providence Regional Cancer System-Aberdeen Suspended
Aberdeen, Washington, United States, 98520
Cancer Care Center at Island Hospital Suspended
Anacortes, Washington, United States, 98221
PeaceHealth Saint Joseph Medical Center Suspended
Bellingham, Washington, United States, 98225
Providence Regional Cancer System-Centralia Suspended
Centralia, Washington, United States, 98531
Swedish Cancer Institute-Edmonds Suspended
Edmonds, Washington, United States, 98026
Providence Regional Cancer Partnership Suspended
Everett, Washington, United States, 98201
Swedish Cancer Institute-Issaquah Suspended
Issaquah, Washington, United States, 98029
Kadlec Clinic Hematology and Oncology Suspended
Kennewick, Washington, United States, 99336
Providence Regional Cancer System-Lacey Suspended
Lacey, Washington, United States, 98503
PeaceHealth Saint John Medical Center Suspended
Longview, Washington, United States, 98632
Pacific Gynecology Specialists Suspended
Seattle, Washington, United States, 98104
Swedish Medical Center-Ballard Campus Suspended
Seattle, Washington, United States, 98107
Fred Hutchinson Cancer Research Center Suspended
Seattle, Washington, United States, 98109
Seattle Cancer Care Alliance Recruiting
Seattle, Washington, United States, 98109
Contact: Site Public Contact    800-804-8824      
Principal Investigator: Leona A. Holmberg         
Kaiser Permanente Washington Active, not recruiting
Seattle, Washington, United States, 98112
Swedish Medical Center-First Hill Suspended
Seattle, Washington, United States, 98122-4307
Swedish Medical Center-Cherry Hill Suspended
Seattle, Washington, United States, 98122-5711
University of Washington Medical Center Suspended
Seattle, Washington, United States, 98195
Providence Regional Cancer System-Shelton Suspended
Shelton, Washington, United States, 98584
Rockwood Clinic Cancer Treatment Center-Valley Suspended
Spokane Valley, Washington, United States, 99216
Rockwood Cancer Treatment Center-DHEC-Downtown Suspended
Spokane, Washington, United States, 99204
Rockwood North Cancer Treatment Center Suspended
Spokane, Washington, United States, 99218
PeaceHealth Southwest Medical Center Suspended
Vancouver, Washington, United States, 98664
Providence Saint Mary Regional Cancer Center Suspended
Walla Walla, Washington, United States, 99362
Providence Regional Cancer System-Yelm Suspended
Yelm, Washington, United States, 98597
United States, Wisconsin
Aurora Cancer Care-Southern Lakes VLCC Recruiting
Burlington, Wisconsin, United States, 53105
Contact: Site Public Contact    414-302-2304    ncorp@aurora.org   
Principal Investigator: Thomas J. Saphner         
Marshfield Clinic-Chippewa Center Suspended
Chippewa Falls, Wisconsin, United States, 54729
Marshfield Clinic Cancer Center at Sacred Heart Suspended
Eau Claire, Wisconsin, United States, 54701
Marshfield Medical Center-EC Cancer Center Recruiting
Eau Claire, Wisconsin, United States, 54701
Contact: Site Public Contact    800-782-8581    oncology.clinical.trials@marshfieldresearch.org   
Principal Investigator: Arlene A. Gayle         
Aurora Health Center-Fond du Lac Recruiting
Fond Du Lac, Wisconsin, United States, 54937
Contact: Site Public Contact    414-302-2304    ncorp@aurora.org   
Principal Investigator: Thomas J. Saphner         
Aurora Health Care Germantown Health Center Recruiting
Germantown, Wisconsin, United States, 53022
Contact: Site Public Contact    414-302-2304    ncorp@aurora.org   
Principal Investigator: Thomas J. Saphner         
Aurora Cancer Care-Grafton Recruiting
Grafton, Wisconsin, United States, 53024
Contact: Site Public Contact    414-302-2304    ncorp@aurora.org   
Principal Investigator: Thomas J. Saphner         
Aurora BayCare Medical Center Recruiting
Green Bay, Wisconsin, United States, 54311
Contact: Site Public Contact    414-302-2304    ncorp@aurora.org   
Principal Investigator: Thomas J. Saphner         
Aurora Cancer Care-Kenosha South Recruiting
Kenosha, Wisconsin, United States, 53142
Contact: Site Public Contact    414-302-2304    ncorp@aurora.org   
Principal Investigator: Thomas J. Saphner         
Marshfield Clinic - Ladysmith Center Suspended
Ladysmith, Wisconsin, United States, 54848
University of Wisconsin Hospital and Clinics Recruiting
Madison, Wisconsin, United States, 53792
Contact: Site Public Contact    800-622-8922      
Principal Investigator: Vaishalee P. Kenkre         
Aurora Bay Area Medical Group-Marinette Recruiting
Marinette, Wisconsin, United States, 54143
Contact: Site Public Contact    414-302-2304    ncorp@aurora.org   
Principal Investigator: Thomas J. Saphner         
Marshfield Medical Center-Marshfield Suspended
Marshfield, Wisconsin, United States, 54449
Marshfield Medical Center Suspended
Marshfield, Wisconsin, United States, 54449
Aurora Cancer Care-Milwaukee Recruiting
Milwaukee, Wisconsin, United States, 53209
Contact: Site Public Contact    414-302-2304    ncorp@aurora.org   
Principal Investigator: Thomas J. Saphner         
Aurora Saint Luke's Medical Center Recruiting
Milwaukee, Wisconsin, United States, 53215
Contact: Site Public Contact    414-302-2304    ncorp@aurora.org   
Principal Investigator: Thomas J. Saphner         
Medical College of Wisconsin Suspended
Milwaukee, Wisconsin, United States, 53226
Aurora Sinai Medical Center Recruiting
Milwaukee, Wisconsin, United States, 53233
Contact: Site Public Contact    414-302-2304    ncorp@aurora.org   
Principal Investigator: Thomas J. Saphner         
Marshfield Clinic-Minocqua Center Recruiting
Minocqua, Wisconsin, United States, 54548
Contact: Site Public Contact    800-782-8581    oncology.clinical.trials@marshfieldresearch.org   
Principal Investigator: Arlene A. Gayle         
Vince Lombardi Cancer Clinic - Oshkosh Recruiting
Oshkosh, Wisconsin, United States, 54904
Contact: Site Public Contact    414-302-2304    ncorp@aurora.org   
Principal Investigator: Thomas J. Saphner         
Aurora Cancer Care-Racine Recruiting
Racine, Wisconsin, United States, 53406
Contact: Site Public Contact    414-302-2304    ncorp@aurora.org   
Principal Investigator: Thomas J. Saphner         
Marshfield Medical Center-Rice Lake Recruiting
Rice Lake, Wisconsin, United States, 54868
Contact: Site Public Contact    800-782-8581    oncology.clinical.trials@marshfieldresearch.org   
Principal Investigator: Arlene A. Gayle         
Vince Lombardi Cancer Clinic-Sheboygan Recruiting
Sheboygan, Wisconsin, United States, 53081
Contact: Site Public Contact    414-302-2304    ncorp@aurora.org   
Principal Investigator: Thomas J. Saphner         
Marshfield Clinic Stevens Point Center Recruiting
Stevens Point, Wisconsin, United States, 54482
Contact: Site Public Contact    800-782-8581    oncology.clinical.trials@marshfieldresearch.org   
Principal Investigator: Arlene A. Gayle         
Aurora Medical Center in Summit Recruiting
Summit, Wisconsin, United States, 53066
Contact: Site Public Contact    414-302-2304    ncorp@aurora.org   
Principal Investigator: Thomas J. Saphner         
Vince Lombardi Cancer Clinic-Two Rivers Recruiting
Two Rivers, Wisconsin, United States, 54241
Contact: Site Public Contact    414-302-2304    ncorp@aurora.org   
Principal Investigator: Thomas J. Saphner         
Marshfield Clinic-Wausau Center Suspended
Wausau, Wisconsin, United States, 54401
Aurora Cancer Care-Milwaukee West Recruiting
Wauwatosa, Wisconsin, United States, 53226
Contact: Site Public Contact    414-302-2304    ncorp@aurora.org   
Principal Investigator: Thomas J. Saphner         
Aurora West Allis Medical Center Recruiting
West Allis, Wisconsin, United States, 53227
Contact: Site Public Contact    414-302-2304    ncorp@aurora.org   
Principal Investigator: Thomas J. Saphner         
Marshfield Clinic - Weston Center Recruiting
Weston, Wisconsin, United States, 54476
Contact: Site Public Contact    800-782-8581    oncology.clinical.trials@marshfieldresearch.org   
Principal Investigator: Arlene A. Gayle         
Marshfield Clinic - Wisconsin Rapids Center Suspended
Wisconsin Rapids, Wisconsin, United States, 54494
United States, Wyoming
Cheyenne Regional Medical Center-West Suspended
Cheyenne, Wyoming, United States, 82001
Billings Clinic-Cody Suspended
Cody, Wyoming, United States, 82414
Saudi Arabia
King Faisal Specialist Hospital and Research Centre Recruiting
Riyadh, Saudi Arabia, 11211
Contact: Site Public Contact    011-966-1-464-7272 ext 38005      
Principal Investigator: Muhammad S. Rauf         
Sponsors and Collaborators
National Cancer Institute (NCI)
Investigators
Layout table for investigator information
Principal Investigator: Charalambos B Andreadis Alliance for Clinical Trials in Oncology

Layout table for additonal information
Responsible Party: National Cancer Institute (NCI)
ClinicalTrials.gov Identifier: NCT02443077     History of Changes
Other Study ID Numbers: NCI-2015-00668
NCI-2015-00668 ( Registry Identifier: CTRP (Clinical Trial Reporting Program) )
BMT CTN 1201
A051301
A051301 ( Other Identifier: Alliance for Clinical Trials in Oncology )
A051301 ( Other Identifier: CTEP )
U10CA180821 ( U.S. NIH Grant/Contract )
First Posted: May 13, 2015    Key Record Dates
Last Update Posted: October 18, 2019
Last Verified: October 2019
Additional relevant MeSH terms:
Layout table for MeSH terms
Lymphoma
Lymphoma, B-Cell
Lymphoma, Large B-Cell, Diffuse
Neoplasms by Histologic Type
Neoplasms
Lymphoproliferative Disorders
Lymphatic Diseases
Immunoproliferative Disorders
Immune System Diseases
Lymphoma, Non-Hodgkin
Cytarabine
Cyclophosphamide
Melphalan
Carmustine
Mechlorethamine
Nitrogen Mustard Compounds
Etoposide
Etoposide phosphate
Immunosuppressive Agents
Immunologic Factors
Physiological Effects of Drugs
Antirheumatic Agents
Antineoplastic Agents, Alkylating
Alkylating Agents
Molecular Mechanisms of Pharmacological Action
Antineoplastic Agents
Myeloablative Agonists
Antineoplastic Agents, Phytogenic
Topoisomerase II Inhibitors
Topoisomerase Inhibitors